Compare Merck & Co., Inc. (MRK) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Global X SuperDividend ETF — how do they compare? Merck & Co., Inc. trades at $147.98 (market cap $363.98B), while Global X SuperDividend ETF trades at $25.24. The key difference: Merck & Co., Inc. pays a 2.3% dividend while Global X SuperDividend ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SDIV | |
|---|---|---|
Market Cap | $363.98B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $26.34 |
52-Week Low | $77.60 | $22.90 |
Enterprise Value | $410.75B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SDIV trades at $25.07, down 0.16% with a bullish technical signal from moving averages. The ETF maintains a consistent $0.18 monthly dividend payment schedule through mid-2026, providing income stability. Recent news highlights SDIV's 9.29% yield and diversification benefits away from tech-heavy portfolios, though questions remain about dividend sustainability.
The outlook balances high income generation against sustainability concerns. Key opportunities include attractive yield in a low-rate environment and non-tech diversification, while risks center on dividend coverage and sensitivity to global economic conditions. Technical strength supports near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
